CATIE urges earlier hepatitis B protection as Canada moves toward routine infant vaccination

CATIE’s November 5 response to Canada’s revised hepatitis B vaccination advice puts a practical question before community pharmacy teams: how can families understand an earlier start to protection without mistaking a national recommendation for an immediate change to their local schedule? The organization welcomed the shift and called for timely implementation. CATIE’s statement is advocacy, not a new provincial funding directive.

Key takeaways

• The fresh development is CATIE’s November response. The underlying National Advisory Committee on Immunization (NACI) statement dates from October 2026.
• NACI recommends routine hepatitis B vaccination for all infants, with program options for starting at birth or at two months.
• A routine schedule must not be confused with urgent management of a baby born to a parent with hepatitis B or an unknown infection status.

Earlier protection, with implementation still to check

NACI’s published summary describes a first dose within 24 hours of birth or at two months, depending on epidemiology and program considerations. It also maintains the importance of prenatal screening and appropriate protection for newborns with a possible exposure. Moving routine vaccination earlier is not a reason to relax those safeguards.

The recommendation also has a transition dimension. Children who have not received an infant series still need a route to protection as programs change. A headline about infant vaccination should not leave families thinking an existing school-based offer no longer matters. The correct schedule for an individual child depends on documented doses and the program operating where the child lives.

Why this matters beyond a vaccination appointment

Hepatitis B can cause persistent infection and later liver disease, including cirrhosis and liver cancer. Infection acquired early in life is particularly likely to become chronic. The Canadian Immunization Guide’s background chapter explains the disease and prevention framework, but its update notice matters: the October 2026 NACI statement should be consulted for the revised recommendation, rather than assuming an older chapter already incorporates it.

Pharmacies may not be the place where a newborn receives a first dose, yet they are often where parents ask what a new health announcement means. A useful conversation can identify which local service provides infant vaccination, whether records are available and which questions need the maternity or public-health team. That is a navigation role; it does not require inventing a new pharmacy service or offering a schedule outside local authority.

Practice guidance for pharmacists

• Check the current provincial or territorial infant schedule before telling a family that implementation has changed.
• Ask about documented doses and direct families to the service responsible for completing the age-appropriate series.
• For questions about a newborn’s possible exposure, direct the family promptly to the treating maternity, pediatric or public-health team rather than treating it as routine scheduling.
• Explain that national recommendations, program funding and the place of administration are separate decisions.
• Update staff reference material with the date of the NACI statement and a link to local implementation guidance.

What happens next is local implementation and communication. A careful pharmacy response can support earlier protection while keeping the distinction between routine prevention, catch-up vaccination and newborn exposure management clear.